Organization
Phost'In Therapeutics
1 clinical trial
Clinical trial
An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Patients With Advanced Solid Tumours (PhAST Trial)Status: Recruiting, Estimated PCD: 2024-07-08